Deloitte Corporate Finance LLC Advises Sina Drug Corporation in its Investment from PharMerica Corporation

Published on : Wednesday, February 5, 2014

DELOITTE-300x118Deloitte Corporate Finance LLC (“DCF”) acted as the exclusive financial advisor to Sina Drug Corporation (DBA “Onco360”) in its investment from PharMerica Corporation (“PharMerica”). As the largest independent provider of oncology pharmacy services in the United States, Onco360 will serve as a key strategic addition to PharMerica’s pharmacy and care management platform.

“Onco360 has built a reputation as a specialty oncology pharmacy and clinical support services organization, and we were pleased to have advised them in this transaction,” said Dave Vorhoff, managing director, DCF, and co-head of DCF’s life sciences and healthcare group.

Source:- Deloitte

Tags:

Comments are closed.

arrow2Follow Us
 
facebook-logo  twitter-logo  LinkedIn_logo  stumbleupon-logo   rss_logo 

SUBSCRIBE NEWSLETTER:

Email 
 

ADVERTISEMENT

    TRAVEL INDUSTRY EVENTS

    More Events...